ClinicalInterests

Dr. Cheng is good at surgical treatment andminimally invasive treatment for various breast diseases. She has rich clinicalexperience in the early diagnosis of breast cancer, and has master modifiedradical mastectomy and breast-conserving surgery for breast cancer. She hasdeep knowledge in breast cancer chemotherapy, endocrine therapy, targetedtherapy and other individualized comprehensive treatments of breast cancer. Shealso has extensive clinical experience in the diagnosis and treatment of benignbreast diseases like mammary gland hyperplasia, breast fibroadenoma, mastitis,breast cyst, etc.

Education

Southern Medical University China Guangzhou,Guangdong, CN

2010-09 to 2015-06 | MBBS

Southern Medical University China Guangzhou,Guangdong, CN

2015-09 to 2018-06 | MD

Publications

1.       Cheng Minyi*, Zhuang Xiaosheng*, ZhangLiulu, Yang Ciqiu, Gao Hongfei, Wang Kun. (2020). A nomogram to predictnon-sentinel lymph node metastasis in patients with initial cN+ breast cancerthat downstages to cN0 after neoadjuvant chemotherapy. J Surg Oncol, doi:10.1002/jso.25989

2. ZhuT, XuFP, Zhang LL, ZhangYF, Yang CC, Cheng MY, Chen FL, WangK.Measurement of molecular biomarkers that predict the tumor response in estrogenreceptor-positive breast cancers after dose-dense (biweekly)paclitaxel/carboplatin neoadjuvant chemotherapy. Oncotarget,2017;8:101087-101094

3.       Zhang L, Huang Y, Yang C, Zhu T, Lin Y,Gao H, Yang M, Cheng M, Wang K. Application ofa carbon nanoparticle suspension for sentinellymph     node mapping in patients with early breastcancer: a retrospective cohort study. World J Surg Oncol. 2018；16(1):112.

4.       Gao HF, Yang CQ, Cheng MY, Zhu T, YangM, Zhang LL, Wang K. Prognostic Significance of Mesenchymal-EpithelialTransition in Triple-Negative Breast Cancers. Clin Breast Cancer. 2018 ;18(5):e961-e966.

5.       Ji F, Yang CQ, Li XL, Zhang LL, Yang M,Li JQ, Gao HF, Zhu T, Cheng MY, Li WP, Wu SY, Zhong AL, Wang K. Riskof breast cancer-related death in women with aprior cancer. Aging(Albany NY). 2020 ;12. doi:10.18632/aging.102984.  5894-5906

6.       Li WP, Zhu T, Hu MX, Yang M, Ji F, GaoHF, Yang CQ, Zhang LL, Cheng MY, Xu FP, Wang K. Comparison of the efficacy andsafety of the EC-T (epirubicin/cyclophosphamide followed by docetaxel) and TCb(docetaxel/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-IIIbreast cancer. NEOPLASMA accepted. doi:10.4149/neo_2020_200130N96 1409-1415

7.       Zhuang XS, Chen C, Liu ZY, Zhang LL,Zhou XZ, Cheng MY, Ji F, Zhu T, Lei CQ, Zhang JS, Jiang JY, Tian J and Wang K.Multiparametric MRI‑based radiomics analysis for the prediction of breast tumorregression patterns after neoadjuvant chemotherapy. Transl Oncol [inpress].doi; 10.1016/j.tranon.2020.100831

8. Wei-Ping Li,Hong-Fei Gao,Fei Ji,Teng Zhu,Min-Yi Cheng,Mei Yang,Ci-Qiu Yang,Liu-Lu Zhang,Jie-Qing Li,Jun-Sheng Zhang ,Kun Wang The role of adjuvantchemotherapy in stage I–III male breast cancer: a SEER-based analysis.  Ther Adv MedOncol 2020V12N:1758835920958358；1758-8340